The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Cited by
Sorted by citations
Items 301–400 of 1,002
Nanoparticle Design Strategies for Effective Cancer Immunotherapy
Velpurisiva, P., Gad, A. P., Piel, B. P., Jadia, R., & Rai, P. (2017) · Journal of Biomedicine · doi:10.7150/jbm.18877 · Cited by 67
An engineered protein antagonist of K-Ras/B-Raf interaction
Kauke, M. J., Traxlmayr, M. W., Parker, J. A., Kiefer, J. D., Knihtila, R., McGee, J., Verdine, G., Mattos, C., & Wittrup, K. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05889-7 · Cited by 64
Zhang, X., Qi, Y. A., Zhang, Q., & Liu, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109542 · Cited by 65
The Black Hole: CAR T Cell Therapy in AML
Atilla, E., & Benabdellah, K. (2023) · Cancers · doi:10.3390/cancers15102713 · Cited by 68
Novel Approaches to Acute Myeloid Leukemia Immunotherapy
Beyar‐Katz, O., & Gill, S. I. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3016 · Cited by 65
van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63
Lu, Y., Zheng, Z., Lowery, F. J., Gartner, J. J., Prickett, T. D., Robbins, P. F., & Rosenberg, S. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002595 · Cited by 63
Self-citationWang, W., Yuan, T., Ma, L., Zhu, Y., Bao, J., Zhao, X., Zhao, Y., Zong, Y., Zhang, Y., Yang, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105810 · Cited by 63
Mapping the MHC Class I–Spliced Immunopeptidome of Cancer Cells
Liepe, J., Sidney, J., Lorenz, F. K. M., Sette, A., & Mishto, M. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0424 · Cited by 62
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 62
Kaliszewski, K., Ludwig, M., Ludwig, B., Mikuła, A., Greniuk, M., & Rudnicki, J. (2022) · Cancers · doi:10.3390/cancers14153643 · Cited by 63
Biomarkers for response to TIL therapy: a comprehensive review
Albarrán, V., Martinez, P. B., Granhøj, J. S., Borch, T. H., Donia, M., & Svane, I. M. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008640 · Cited by 64
Shared cancer neoantigens: Making private matters public
Klebanoff, C. A., & Wolchok, J. D. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20172188 · Cited by 62
Organoid models of the tumor microenvironment and their applications
Xia, T., Du, W., Chen, X., & Zhang, Y.-N. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16578 · Cited by 63
Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
Li, S., Simoni, Y., Zhuang, S., Gabel, A. M., Ma, S., Chee, J., Islas, L., Cessna, A., Creaney, J., Bradley, R. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025570118 · Cited by 61
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
Kiyotani, K., Chan, T., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13498 · Cited by 61
Lu, Y., Jia, L., Zheng, Z., Tran, E., Robbins, P. F., & Rosenberg, S. A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0299 · Cited by 62
Self-citationSuch, L., Zhao, F., Liu, D. H., Thier, B., Le‐Trilling, V. T. K., Sucker, A., Coch, C., Pieper, N., Howe, S., Bhat, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131572 · Cited by 61
TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
Poorebrahim, M., Mohammadkhani, N., Mahmoudi, R., Gholizadeh, M., Fakhr, E., & Arregui, A. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00307-7 · Cited by 61
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 64
Characterizing neoantigens for personalized cancer immunotherapy
Capietto, A.-H., Jhunjhunwala, S., & Delamarre, L. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.007 · Cited by 63
Sakellariou-Thompson, D., Forget, M., Creasy, C. A., Bernard, V., Zhao, L., Kim, Y. U., Hurd, M. W., Uraoka, N., Parra, E. R., Kang, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0831 · Cited by 60
TCRmodel: high resolution modeling of T cell receptors from sequence
Gowthaman, R., & Pierce, B. G. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky432 · Cited by 60
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
“Clinical evaluations of KRAS inhibitors, sotorasib and adagrasib, were conducted as basket trials and included solid tumors with KRAS G12C regardless of the tissue of origin.”
BackgroundHu, B., Sajid, M., Lv, R., Liu, L., & Sun, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996721 · Cited by 60
Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Tintelnot, J., & Stein, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3920 · Cited by 59
Cardiotoxic mechanisms of cancer immunotherapy – A systematic review
Lobenwein, D., Kocher, F., Dobner, S., Gollmann‐Tepeköylü, C., & Holfeld, J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.033 · Cited by 59
Lee, W., Reuben, A., Hu, X., McGranahan, N., Chen, R., Jalali, A., Negrao, M. V., Hubert, S. M., Tang, C. Z., Wu, C.-C., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02175-0 · Cited by 60
Amaria, R. N., Knisely, A. T., Vining, D. J., Kopetz, S., Overman, M. J., Javle, M. M., Antonoff, M. B., Tzeng, C.-W. D., Wolff, R. A., Pant, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006822 · Cited by 58
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 58
Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy
Gutwillig, A., Santana-Magal, N., Farhat-Younis, L., Rasoulouniriana, D., Madi, A., Luxenburg, C., Cohen, J., Padmanabhan, K., Shomron, N., Shapira, G., et al. (2022) · eLife · doi:10.7554/elife.80315 · Cited by 59
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67
Immunotherapy in gastrointestinal cancers
Grierson, P. M., Lim, K., & Amin, M. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.05.01 · Cited by 57
Kato, T., Matsuda, T., Ikeda, Y., Park, J.-H., Leisegang, M., Yoshimura, S., Hikichi, T., Harada, M., Zewde, M. G., Sato, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24232 · Cited by 58
Development of adaptive immune effector therapies in solid tumors
Comoli, P., Chabannon, C., Koehl, U., Lanza, F., Urbano-Ispizúa, Á., Hudecek, M., Ruggeri, A., Secondino, S., Bonini, C., & Pedrazzoli, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz285 · Cited by 57
The Tumor Microenvironment of Colorectal Cancer Metastases: Opportunities in Cancer Immunotherapy
Kamal, Y., Schmit, S. L., Frost, H. R., & Amos, C. I. (2020) · Immunotherapy · doi:10.2217/imt-2020-0026 · Cited by 56
Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy
Zhang, X., & Sjöblom, T. (2021) · Pharmaceuticals · doi:10.3390/ph14010057 · Cited by 58
Ou, X., Ma, Q., Yin, W., Ma, X., & He, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674467 · Cited by 58
Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types
Gurung, H. R., Heidersbach, A. J., Darwish, M., Chan, P. P. F., Li, J., Beresini, M. H., Zill, O. A., Wallace, A., Tong, A.-J., Hascall, D., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01945-y · Cited by 59
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy
Brightman, S. E., Naradikian, M. S., Miller, A. M., & Schoenberger, S. P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0220-603rr · Cited by 57
Arbelaez, C. A., Estrada, J., Gessner, M. A., Glaus, C., Morales, A. B., Mohn, D., Phee, H., Lipford, J. R., & Johnston, J. A. (2020) · npj Vaccines · doi:10.1038/s41541-020-00253-9 · Cited by 58
Targeting the undruggable oncogenic KRAS: the dawn of hope
Asimgil, H., Ertetik, U., Çevik, N. C., Ekizce, M., Doğruöz, A., Gökalp, M., Sever, E. A., Istvánffy, R., Friess, H., Ceyhan, G. O., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153688 · Cited by 57
Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches
Choi, S., Park, S., Kim, H., Kang, S. Y., Ahn, S., & Kim, K. (2022) · Biomedicines · doi:10.3390/biomedicines10030543 · Cited by 55
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 57
Tuning cancer fate: the unremitting role of host immunity
Calì, B., Molon, B., & Viola, A. (2017) · Open Biology · doi:10.1098/rsob.170006 · Cited by 58
Levin, N., Paria, B. C., Vale, N. R., Yossef, R., Lowery, F. J., Parkhurst, M. R., Yu, Z., Florentin, M., Cafri, G., Gartner, J. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0849 · Cited by 54
Self-citationBiomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
Gyurdieva, A. V., Zajic, S. C., Chang, Y.-F., Houseman, E. A., Zhong, S., Kim, J., Nathenson, M. J., Faitg, T. H., Woessner, M. A., Turner, D. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32491-x · Cited by 54
Chen, M., Chen, R., Jin, Y., Li, J., Hu, X. Y., Zhang, J., Fujimoto, J., Hubert, S. M., Gay, C. M., Zhu, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26821-8 · Cited by 55
Kuhn, N. F., Lopez, A. V., Li, X., Cai, W., Daniyan, A. F., & Brentjens, R. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19833-3 · Cited by 54
Ros, J., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Cancers · doi:10.3390/cancers15174245 · Cited by 53
Patel, R. K., Rahman, S., Schwantes, I. R., Bartlett, A. Q., Eil, R. L., Farsad, K., Fowler, K. J., Goodyear, S. M., Hansen, L., Kardosh, A., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.08.012 · Cited by 55
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 56
Effern, M., Glodde, N., Braun, M., Liebing, J., Boll, H. N., Yong, M. C. R., Bawden, E., Hinze, D., Konijnenberg, D., Daoud, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.007 · Cited by 55
Personalized cancer vaccination in head and neck cancer
Shibata, H., Zhou, L., Xu, N., Egloff, A. M., & Uppaluri, R. (2020) · Cancer Science · doi:10.1111/cas.14784 · Cited by 54
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 56
T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy
Sim, M. J. W., & Sun, P. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833017 · Cited by 55
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 52
Neoantigen cancer vaccines: a new star on the horizon
Li, X., You, J., Hong, L., Liu, W., Guo, P., & Hao, X. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0395 · Cited by 53
Checkpoint immunotherapy in head and neck cancers
Zolkind, P., & Uppaluri, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9694-9 · Cited by 52
Cancer vaccines: translation from mice to human clinical trials
Maeng, H. M., Terabe, M., & Berzofsky, J. A. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.001 · Cited by 53
Therapeutic vaccines for colorectal cancer: The progress and future prospect
Shahnazari, M., Samadi, P., Pourjafar, M., & Jalali, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106944 · Cited by 53
Fathi, M., Pustokhina, I., Kuznetsov, S. V., Khayrullin, M., Hojjat‐Farsangi, M., Karpisheh, V., Jalili, A., & Jadidi‐Niaragh, F. (2021) · IUBMB Life · doi:10.1002/iub.2461 · Cited by 53
Considerations for personalized neoantigen vaccination in Malignant glioma
Dunn, G. P., Sherpa, N. D., Manyanga, J., & Johanns, T. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114312 · Cited by 51
The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes
Aptsiauri, N., & Garrido, F. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3501 · Cited by 53
Qiu, S., Zhao, Z., Wu, M., Qi, X., Yang, Y., Ouyang, S., Li, W., Zhong, L., Wang, W., Yang, R. L., et al. (2022) · Science Advances · doi:10.1126/sciadv.add2337 · Cited by 51
T cell immunotherapy for cervical cancer: challenges and opportunities
Yu, L., Lanqing, G., Huang, Z., Xin, X., Liang, M., Fa-hui, L., Zou, H., & Min, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105265 · Cited by 51
Low-avidity T cells drive endogenous tumor immunity in mice and humans
Singhaviranon, S., Dempsey, J. P., Hagymasi, A. T., Măndoiu, I., & Srivastava, P. K. (2025) · Nature Immunology · doi:10.1038/s41590-024-02044-z · Cited by 53
Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy
Zhao, X., & Subramanian, S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.004 · Cited by 51
Acquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 51
Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours
Chruściel, E., Urban‐Wójciuk, Z., Arcimowicz, Ł., Kurkowiak, M., Kowalski, J., Gliwiński, M., Marjański, T., Rzyman, W., Biernat, W., Dziadziuszko, R., et al. (2020) · Cancers · doi:10.3390/cancers12030683 · Cited by 53
Noma, T., Makino, T., Ohshima, K., Sugimura, K., Miyata, H., Honma, K., Yamashita, K., Saito, T., Tanaka, K., Yamamoto, K., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005104 · Cited by 50
Recent advances and remaining challenges in lung cancer therapy
Barr, T., Ma, S., Li, Z., & Yu, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002991 · Cited by 52
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Linehan, A., O’Reilly, M., McDermott, R., & O'Kane, G. M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1369136 · Cited by 57
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC
Şahin, U., Schmidt, M., Derhovanessian, E., Cortini, A., Vogler, I., Omokoko, T., Godehardt, E., Attig, S., Newrzela, S., GRUTZNER, J., et al. (2026) · Nature · doi:10.1038/s41586-025-10004-2 · Cited by 50
The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
Kärpänen, T., & Olweus, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01718 · Cited by 50
Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
Zhang, J., Wolfgang, C. L., & Zheng, L. (2018) · Cancers · doi:10.3390/cancers10020039 · Cited by 52
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
Janelle, V., Rulleau, C., Testa, S. D., Carli, C., & Delisle, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00276 · Cited by 52
Lee, M. N., & Meyerson, M. M. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf4001 · Cited by 50
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
Okada, M., Shimizu, K., & Fujii, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052594 · Cited by 50
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Lozano-Rabella, M., García-Garijo, A., Palomero, J., Yuste-Estevanez, A., Erhard, F., Farriol-Duran, R., Martín-Liberal, J., Ochoa-de-Olza, M., Matos, I. G., Gartner, J. J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3298 · Cited by 52
Self-citationMicevic, G., Daniels, A., Karlsen, K. F., Park, K., Talty, R., McGeary, M. K., Mirza, H., Blackburn, H. N., Sefik, E., Cheung, J. F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304319120 · Cited by 49
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Borgers, J. S. W., Lenkala, D., Kohler, V. L., Jackson, E. K., Linssen, M. D., Hymson, S., McCarthy, B. J., Cosgrove, E., Balogh, K. N., Esaulova, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03418-4 · Cited by 50
Erasha, A. M., El-Gendy, H. F., Aly, A. S., Fernández‐Ortiz, M., & Sayed, R. K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062716 · Cited by 52
Stein, A., & Folprecht, G. (2018) · Oncology Research and Treatment · doi:10.1159/000488918 · Cited by 49
Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer
Leko, V., McDuffie, L. A., Zheng, Z., Gartner, J. J., Prickett, T. D., Apolo, A. B., Agarwal, P. K., Rosenberg, S. A., & Lu, Y. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801022 · Cited by 49
Self-citationAn effective mouse model for adoptive cancer immunotherapy targeting neoantigens
Hanada, K., Yu, Z., Chappell, G. R., Park, A. S., & Restifo, N. P. (2019) · JCI Insight · doi:10.1172/jci.insight.124405 · Cited by 49
Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine
Fuentes‐Antrás, J., Guevara‐Hoyer, K., Baliu‐Piqué, M., García-Sáenz, J. Á., Pérez‐Segura, P., Pandiella, A., & Ocaña, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605633 · Cited by 49
Saberian, C., Amaria, R. N., Najjar, A. M., Radvanyi, L. G., Haymaker, C., Forget, M., Bassett, R. L., Faria, S. C., Glitza, I. C., Alvarez, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002449 · Cited by 49
Immunotherapy for Pancreatic Cancer: Present and Future
Aroldi, F., & Zaniboni, A. (2017) · Immunotherapy · doi:10.2217/imt-2016-0142 · Cited by 48
Implementing Logic Gates for Safer Immunotherapy of Cancer
Savanur, M. A., Weinstein-Marom, H., & Gross, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780399 · Cited by 48
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification
Tretter, C., Krätzig, N. D. A., Pecoraro, M., Lange, S., Seifert, P., von Frankenberg, C., Untch, J., Zuleger, G., Wilhelm, M., Zolg, D. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39570-7 · Cited by 49
Mishto, M., Mansurkhodzhaev, A., Ge, Y., Bitra, A., Cordfunke, R. A., Henze, S., Paul, D., Sidney, J., Urlaub, H., Neefjes, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02572 · Cited by 48
Progress in Neoantigen Targeted Cancer Immunotherapies
Han, X., Ma, X., Li, Y., Wei, Y.-Q., Peng, Y., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 49
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
Zou, X.-L., Li, X., Ke, H., Zhang, G., Tang, Q., Yuan, J., Zhou, C.-J., Zhang, J., Zhang, R., & Chen, W.-Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689076 · Cited by 48
New therapeutic opportunities for women with low-grade serous ovarian cancer
Moujaber, T., Balleine, R. L., Gao, B., Madsen, I., Harnett, P. R., & DeFazio, A. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0191 · Cited by 47
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
Mota, I. A., Patrucco, E., Mastini, C., Mahadevan, N. R., Thai, T. C., Bergaggio, E., Cheong, T.-C., Leonardi, G. C., Atabay, E. K., Campisi, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00591-2 · Cited by 47
Imodoye, S. O., Adedokun, K. A., & Bello, I. O. (2024) · Histochemistry and Cell Biology · doi:10.1007/s00418-023-02258-6 · Cited by 47
Immunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2018) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2018.09.002 · Cited by 48
RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
Saeed, O. A. M., Antonio Lopez-beltran, B., Fisher, K. W., Scarpelli, M., Montironi, R., Cimadamore, A., Massari, F., Santoni, M., & Liang Cheng, C. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205471 · Cited by 47
Shared Neoantigens: Ideal Targets for Off-The-Shelf Cancer Immunotherapy
Zhao, W., Wu, J., Chen, S., & Zhou, Z. M. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0184 · Cited by 49
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
